By IDSE News Staff
Sanofi signed an agreement with Roche for the exclusive over-the-counter (OTC) rights to oseltamivir (Tamiflu) for the prevention and treatment of influenza in the United States.
Under the terms of the agreement, Sanofi will be responsible for leading FDA negotiations for the OTC switch and subsequent exclusive marketing, scientific engagement and distribution of oseltamivir OTC in the United States. Branded oseltamivir is currently sold by Genentech, a member of the